This article was originally published in The Gray Sheet
Removable, intracorneal lens implant Phase II study go-ahead from FDA includes 100 eyes at five sites with up to +6 diopters of hyperopia, the firm says. The lens is placed under a corneal flap made with a microkeratome in a reversible, sutureless procedure. The flap is similar to ones in non-reversible LASIK refractive procedures, according to Lake Forest, Calif.-based Anamed...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.